Stock Track | Novavax Soars 5.06% as B. Riley Maintains Buy Rating Despite Lower Price Target

Stock Track

16 hours ago

Novavax (NVAX) shares surged 5.06% in Tuesday's intraday trading session, despite B. Riley adjusting its price target on the stock from $18 to $16. The positive market reaction comes as the financial services firm maintained its "Buy" rating on the vaccine developer's stock.

While the price target reduction might seem counterintuitive to the stock's upward movement, investors appear to be focusing on the maintained "Buy" rating and the fact that the new target price still represents significant upside potential from current levels. B. Riley's continued confidence in Novavax, despite the slight downward adjustment in price expectations, seems to have bolstered investor sentiment.

The broader analyst community also maintains a generally positive outlook on Novavax. According to FactSet, the stock has an average rating of "Overweight" with a mean price target of $13.62. This consensus view, combined with B. Riley's latest assessment, suggests that Wall Street sees potential in Novavax's future performance, driving the stock's impressive gains in today's trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1151674507"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151674507\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151674507?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 02:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151674507","market":"sg","top_or_hot":-1,"title":"Stock Track | Novavax Soars 5.06% as B. Riley Maintains Buy Rating Despite Lower Price Target","media":"Stock Track","content":"<p>Novavax (NVAX) shares surged 5.06% in Tuesday's intraday trading session, despite B. Riley adjusting its price target on the stock from $18 to $16. The positive market reaction comes as the financial services firm maintained its \"Buy\" rating on the vaccine developer's stock.</p>\n\n<p>While the price target reduction might seem counterintuitive to the stock's upward movement, investors appear to be focusing on the maintained \"Buy\" rating and the fact that the new target price still represents significant upside potential from current levels. B. Riley's continued confidence in Novavax, despite the slight downward adjustment in price expectations, seems to have bolstered investor sentiment.</p>\n\n<p>The broader analyst community also maintains a generally positive outlook on Novavax. According to FactSet, the stock has an average rating of \"Overweight\" with a mean price target of $13.62. This consensus view, combined with B. Riley's latest assessment, suggests that Wall Street sees potential in Novavax's future performance, driving the stock's impressive gains in today's trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novavax Soars 5.06% as B. Riley Maintains Buy Rating Despite Lower Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Soars 5.06% as B. Riley Maintains Buy Rating Despite Lower Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 02:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax (NVAX) shares surged 5.06% in Tuesday's intraday trading session, despite B. Riley adjusting its price target on the stock from $18 to $16. The positive market reaction comes as the financial services firm maintained its \"Buy\" rating on the vaccine developer's stock.</p>\n\n<p>While the price target reduction might seem counterintuitive to the stock's upward movement, investors appear to be focusing on the maintained \"Buy\" rating and the fact that the new target price still represents significant upside potential from current levels. B. Riley's continued confidence in Novavax, despite the slight downward adjustment in price expectations, seems to have bolstered investor sentiment.</p>\n\n<p>The broader analyst community also maintains a generally positive outlook on Novavax. According to FactSet, the stock has an average rating of \"Overweight\" with a mean price target of $13.62. This consensus view, combined with B. Riley's latest assessment, suggests that Wall Street sees potential in Novavax's future performance, driving the stock's impressive gains in today's trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1151674507","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151674507","pubTimestamp":1762887270,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novavax (NVAX) shares surged 5.06% in Tuesday's intraday trading session, despite B. Riley adjusting its price target on the stock from $18 to $16. The positive market reaction comes as the financial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"个股追踪|Novavax飙升5.06%，尽管目标价较低，B.Riley仍维持买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Novavax (NVAX) shares surged 5.06% in Tuesday's intraday trading session, despite B. Riley adjusting its price target on the stock from $18 to $16. The positive market reaction comes as the financial services firm maintained its \"Buy\" rating on the vaccine developer's stock.\nWhile the price target reduction might seem counterintuitive to the stock's upward movement, investors appear to be focusing on the maintained \"Buy\" rating and the fact that the new target price still represents significant upside potential from current levels. B. Riley's continued confidence in Novavax, despite the slight downward adjustment in price expectations, seems to have bolstered investor sentiment.\nThe broader analyst community also maintains a generally positive outlook on Novavax. According to FactSet, the stock has an average rating of \"Overweight\" with a mean price target of $13.62. This consensus view, combined with B. Riley's latest assessment, suggests that Wall Street sees potential in Novavax's future performance, driving the stock's impressive gains in today's trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}